FDA advisory panels recommend Lotronex be put back on market.
Charatan
Fred
F
D026683:Advisory Committees; D002243:Carbolines / Q000009:adverse effects / Q000627:therapeutic use*; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D017277:Drug Approval; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration
D002243:Carbolines; D005765:Gastrointestinal Agents; C090840:alosetron